Overview
Dravet syndrome (DS) is a rare, catastrophic form of epilepsy that begins in the first year of life. Fenfluramine and the metabolite, norfenfluramine, increase extracellular levels of serotonin through interaction with serotonin transporter proteins, and exhibit agonist activity at serotonin 5HT-2 receptors.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Fintepla, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs. OR
Authorization may be granted when all the following diagnosis specific criteria are met, and documentation has been provided:
1. The member has a diagnosis of seizures associated with Dravet syndrome
2. The member is ≥ 2 years old
3. Prescriber is a neurologist or documentation provided of recent neurology consultation
4. Member has had an inadequate response or adverse reaction to at least 2 of the following anticonvulsant agents OR a contraindication to ALL the following agents:
   a. clobazam
   b. clonazepam
   c. ethosuximide
   d. levetiracetam
   e. phenobarbital
   5. stiripentol
   6. topiramate
   7. valproic acid
   8. zonisamide

Continuation of Therapy
Reauthorization may be approved when physician assessment has been provided documenting a decrease in the number of seizures.
Limitations
1. Initial approvals will be approved for 3 months
2. Reauthorizations will be approved for 12 months

<table>
<thead>
<tr>
<th>Fintepla</th>
<th>360mL per 30 days</th>
</tr>
</thead>
</table>

Dosing recommendation
Pediatric (≥ 2 years to 18 years):
- 0.1 mg/kg/dose twice daily
- 0.2 mg/kg/dose twice daily
- 0.35 mg/kg/dose twice daily

Maximum dose: 13 mg/dose twice daily

References

Review History

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.